Publikationer pr. år
Publikationer 2000 2019
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
PRIMA/ENGOT-OV26/GOG-3012 Investigators, González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., Baumann, K., Jardon, K., Redondo, A., Moore, R. G., Vulsteke, C., O'Cearbhaill, R. E., Lund, B., Backes, F., Barretina-Ginesta, P. & 11 flere, , 28 sep. 2019, I : The New England Journal of Medicine.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
Del Campo, J. M., Matulonis, U. A., Malander, S., Provencher, D., Mahner, S., Follana, P., Waters, J., Berek, J. S., Woie, K., Oza, A. M., Canzler, U., Gil-Martin, M., Lesoin, A., Monk, B. J., Lund, B., Gilbert, L., Wenham, R. M., Benigno, B., Arora, S., Hazard, S. J. & 1 flere, , 10 nov. 2019, I : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 32, s. 2968-2973 6 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
Mirza, M. R., Åvall Lundqvist, E., Birrer, M. J., dePont Christensen, R., Nyvang, G-B., Malander, S., Anttila, M., Werner, T. L., Lund, B., Lindahl, G., Hietanen, S., Peen, U., Dimoula, M., Roed, H., Ør Knudsen, A., Staff, S., Krog Vistisen, A., Bjørge, L., Mäenpää, J. U., AVANOVA investigators & 1 flere, , okt. 2019, I : The Lancet. Oncology. 20, 10, s. 1409-1419 11 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
Oza, A. M., Matulonis, U. A., Malander, S., Hudgens, S., Sehouli, J., Del Campo, J. M., Berton-Rigaud, D., Banerjee, S., Scambia, G., Berek, J. S., Lund, B., Tinker, A. V., Hilpert, F., Vázquez, I. P., D'Hondt, V., Benigno, B., Provencher, D., Buscema, J., Agarwal, S. & Mirza, M. R., 2018, I : The Lancet. Oncology. 19, 8, s. 1117-1125 9 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer
Dahl Steffensen, K., Waldstrøm, M., Brandslund, I., Lund, B., Mejer Sørensen, S., Petzold, M. & Jakobsen, A., 2016, I : Oncology Letters. 11, 6, s. 3967-3974 8 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
du Bois, A., Kristensen, G., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I., Del Campo, J. M., Ottevanger, P., Heubner, M., Minarik, T., Sevin, E., de Gregorio, N., Bidziński, M., Pfisterer, J., Malander, S., Hilpert, F., Mirza, M. R., Scambia, G. & 8 flere, , jan. 2016, I : Lancet Oncology. 17, 1, s. 78-89 12 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T-W., Rustin, G., Joly, F., Mirza, M. R., Plante, M., Quinn, M. S., Poveda, A., Jayson, G. C., Stark, D., Swart, A. M. & 5 flere, , aug. 2015, I : Lancet Oncology. 16, 8, s. 928-936 9 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer
Wang, Y., Herrstedt, J., Havsteen, H., Christensen, R. D., Mirza, M. R., Lund, B., Maenpaa, J. & Kristensen, G., 2014, I : B M C Cancer. 2014, 14, 937.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Vellykket behandling af lokal avanceret, småcellet, neuroendokrint cervixkarcinom
Rasmussen, L. B., Lindegaard, J. C., Lund, B., Grove, A. & Fokdal, L. U., 2014, I : Ugeskrift for Laeger. 176, 2 s., V06140374.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study
Steffensen, K. D., Waldstrøm, M., Pallisgård, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. & Jakobsen, A., 1 jan. 2013, I : International Journal of Gynecological Cancer. 23, 1, s. 73-80 8 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Primært malignt melanom i vagina
Kahr, H. S., Mejlgaard, E. & Lund, B., 14 jan. 2013, I : Ugeskrift for Laeger. 175, 3, s. 133-4 2 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial
Brundage, M., Gropp, M., Mefti, F., Mann, M. K., Lund, B., Gebski, V., Wolfram, G., Reed, N., Pignata, S., Ferrero, A., Brown, J. C., Eisenhauer, E. & Pujade-Lauraine, E., aug. 2012, I : Annals of Oncology. 23, 8, s. 2020-7 8 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
A phase 3 trial of bevacizumab in ovarian cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stähle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R. & 7 flere, , 29 dec. 2011, I : The New England Journal of Medicine. 365, 26, s. 2484-96 13 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Improved Classification of Epithelial Ovarian Cancer: Results of 3 Danish Cohorts
Steffensen, K. D., Waldstrom, M., Grove, A., Lund, B., Pallisgard, N. & Jakobsen, A., 16 sep. 2011, I : International Journal of Gynecological Cancer. 21, s. 1592-1600 9 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Radiobiological impact of reduced margins and treatment technique for prostate cancer in terms of tumor control probability (TCP) and normal tissue complication probability (NTCP)
Jensen, I., Carl, J., Lund, B., Larsen, E. H. & Nielsen, J. N., 2011, I : Medical Dosimetry. 36, s. 130-7 8 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin
Mirza, M. R., Lund, B., Lindegaard, J. C., Keldsen, N., Mellemgaard, A., Christensen, R. D. & Bertelsen, K., 1 okt. 2010, I : Gynecologic Oncology. 119, s. 26-31 6 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Automated detection of a prostate Ni-Ti stent in electronic portal images.
Carl, J. H., Nielsen, H., Nielsen, J., Lund, B. & Larsen, E. H., 2006, I : Medical Physics. 33, 12, s. 4600-4605 6 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Feasibility study using a Ni-Ti stent and electronic portal imaging to localize the prostate during radiotherapy.
Carl, J. H., Lund, B., Larsen, E. H. & Nielsen, J., 2006, I : Radiotherapy and Oncology. 78, s. 199-206Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC
Bois, A. D., Sehouli, J., Lund, B., Joly, E., Huober, J., Jensen, TS., Levy, E., Heilmann, V., Boman, K., Hardy-Bessard, AC., Burges, A., Maenpaa, J., Pujade-Lauraine, E., Pfisterer, J., Gropp, M., Staehle, A., Wimberger, P., Jackisch, C., Schmalfeldt, B., Belau, A. & 5 flere, , 1 nov. 2005, I : International Journal of Gynecological Cancer. 15, Suppl. 3, s. 224-225 2 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark
Andersen, E. S., Knudsen, A., Svarrer, T., Lund, B., Nielsen, K., Grove, A. & Tetsche, M. S., 2005, I : Gynecologic Oncology. 99, 3, s. 552-556 5 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer
Underhill, CR., Parnis, FX., Highley, MS., Ahern, J., Harper, PG., Hansen, H., Lund, B., Dombernowsky, P., Hirsch, F., Hansen, M., Carmichael, J. & Williams, H. C., 1 sep. 2001, I : Anti-Cancer Drugs. 12, 8, s. 647-652 6 s.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review